|
1
|
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
|
Lancet
|
2007
|
7.01
|
|
2
|
VEGF links hippocampal activity with neurogenesis, learning and memory.
|
Nat Genet
|
2004
|
3.60
|
|
3
|
AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats.
|
Mol Cell Neurosci
|
2005
|
1.92
|
|
4
|
Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.
|
Mol Ther
|
2009
|
1.66
|
|
5
|
Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development.
|
Eur J Neurosci
|
2003
|
1.32
|
|
6
|
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
|
Mol Ther
|
2008
|
1.31
|
|
7
|
Development and optimization of adeno-associated virus vector transfer into the central nervous system.
|
Methods Mol Med
|
2003
|
1.23
|
|
8
|
Long-term follow-up after gene therapy for canavan disease.
|
Sci Transl Med
|
2012
|
1.22
|
|
9
|
IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice.
|
J Clin Invest
|
2008
|
1.17
|
|
10
|
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease.
|
Mol Ther
|
2004
|
1.16
|
|
11
|
In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.
|
MAbs
|
2010
|
1.09
|
|
12
|
Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
|
Mol Ther
|
2005
|
1.08
|
|
13
|
Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels.
|
Mol Neurodegener
|
2007
|
1.06
|
|
14
|
IL-21 receptor is critical for the development of memory B cell responses.
|
J Immunol
|
2010
|
1.05
|
|
15
|
Somatic gene transfer of cAMP response element-binding protein attenuates memory impairment in aging rats.
|
Proc Natl Acad Sci U S A
|
2006
|
1.03
|
|
16
|
IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
|
J Immunol
|
2012
|
1.02
|
|
17
|
Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice.
|
Epilepsia
|
2006
|
0.97
|
|
18
|
A novel role of circadian transcription factor DBP in hippocampal plasticity.
|
Mol Cell Neurosci
|
2005
|
0.97
|
|
19
|
IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response.
|
Diabetes
|
2011
|
0.92
|
|
20
|
Identification and distribution of aspartoacylase in the postnatal rat brain.
|
Neuroreport
|
2003
|
0.92
|
|
21
|
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
|
J Transl Med
|
2010
|
0.90
|
|
22
|
Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis.
|
Arthritis Rheumatol
|
2014
|
0.87
|
|
23
|
Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size.
|
Stroke
|
2013
|
0.86
|
|
24
|
Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia.
|
J Neurochem
|
2007
|
0.85
|
|
25
|
Knockdown and overexpression of NR1 modulates NMDA receptor function.
|
Mol Cell Neurosci
|
2009
|
0.84
|
|
26
|
Maximizing children's physical activity: an evaluability assessment to plan a community-based, multi-strategy approach in an ethno-racially and socio-economically diverse city.
|
Health Promot Int
|
2003
|
0.84
|
|
27
|
Gene regulation systems for gene therapy applications in the central nervous system.
|
Neurol Res Int
|
2012
|
0.83
|
|
28
|
Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood.
|
J Transl Med
|
2010
|
0.80
|
|
29
|
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.
|
J Transl Med
|
2010
|
0.80
|
|
30
|
Nucleic Acid-Based Therapy Approaches for Huntington's Disease.
|
Neurol Res Int
|
2012
|
0.80
|
|
31
|
HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity.
|
Mol Ther
|
2008
|
0.79
|
|
32
|
Phosphorylation-dependent degradation of transgenic CREB protein initiated by heterodimerization.
|
Brain Res
|
2006
|
0.76
|
|
33
|
TERN Residency Program: transitioning the experienced registered nurse.
|
J Nurses Prof Dev
|
2014
|
0.75
|